Open AccessMac‐2‐binding protein glycan isomer predicts all malignancies after sustained virological response in chronic hepatitis C
Author(s) -
Kawata Kazuhito,
Atsukawa Masanori,
Ohta Kazuyoshi,
Chida Takeshi,
Noritake Hidenao,
Arai Taeang,
Iwakiri Katsuhiko,
Yasuda Satoshi,
Toyoda Hidenori,
Okubo Tomomi,
Hiraoka Atsushi,
Watanabe Tsunamasa,
Uojima Haruki,
Nozaki Akito,
Tani Joji,
Morishita Asahiro,
Kageyama Fujito,
Sasada Yuzo,
Nagasawa Masamichi,
Matsushita Masahiro,
Oyaizu Tatsuki,
Mikami Shigeru,
Ikegami Tadashi,
Abe Hiroshi,
Matsuura Kentaro,
Tanaka Yasuhito,
Tsubota Akihito
Publication year - 2022
Publication title -
hepatology communications
Language(s) - English
Resource type - Journals
ISSN - 2471-254X
DOI - 10.1002/hep4.1941
Subject(s) - hepatocellular carcinoma , medicine , incidence (geometry) , malignancy , gastroenterology , proportional hazards model , hepatitis c virus , hepatitis c , cumulative incidence , cancer , oncology , immunology , virus , cohort , physics , optics
Despite reports of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C virus (HCV) infection after achieving sustained virological response (SVR), only few studies have demonstrated the incidence of other (non‐HCC) malignancies. This study aimed to clarify the incidence, survival probability, and factors associated with malignancy, especially non‐HCC malignancies, in patients with chronic HCV infection after achieving SVR. In this retrospective study, records of 3580 patients with chronic HCV infection who achieved SVR following direct‐acting antiviral (DAA) treatment were analyzed. The cumulative post‐SVR incidence of non‐HCC malignancies was 0.9%, 3.1%, and 6.8% at 1, 3, and 5 years, respectively. The survival probability for patients with non‐HCC malignancies was 99.1%, 78.8%, and 60.2% at 1, 3, and 5 years, respectively, and the rate was significantly lower than that for patients with HCC. The Cox proportional hazards regression model identified Mac‐2‐binding protein glycan isomer (M2BPGi) cutoff index (COI) ≥ 1.90 at baseline and ≥ 1.50 at 12 weeks following DAA treatment as significant and independent factors associated with the post‐SVR incidence of non‐HCC malignancies. Furthermore, patients with either M2BPGi COI ≥ 1.90 at baseline or M2BPGi COI ≥ 1.50 at SVR12 had a significantly higher risk of post‐SVR incidence of non‐HCC malignancies than of HCC. Conclusion: M2BPGi measurements at baseline and SVR12 may help predict the post‐SVR incidence of non‐HCC malignancies in patients with chronic HCV infection who achieved SVR following DAA treatment. Early identification of these patients is critical to prolong patient survival.